...
首页> 外文期刊>Expert review of hematology >Highlights in lymphoma: Overview of the 11th International Conference on Malignant Lymphoma
【24h】

Highlights in lymphoma: Overview of the 11th International Conference on Malignant Lymphoma

机译:淋巴瘤的亮点:第十一届国际恶性淋巴瘤会议概述

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The 11th International Conference on Malignant Lymphoma (ICML), the main international forum devoted to basic and clinical research in lymphoid neoplasms, took place in Lugano, Switzerland, from 15 to 18 June 2011. In 2011, 3200 experts in lymphoma from 76 countries attended the meeting. ICML represents the most important forum for the discussion of all aspects relating to basic research, clinical data and results of trials in the treatment of malignant lymphoma worldwide. The incidence of Hodgkin's and non-Hodgkin's lymphoma is increasing. Treatment of lymphoma is heterogeneous, with effective results seen with standard chemotherapy, immunotherapy, high-dose chemotherapy with transplantation and radiotherapy. The biological basis of the growth of lymphoma explains the rationale for the introduction of experimental new drugs in monotherapy or in combination with consolidate schemes. The results have been promising and these issues were discussed during the meeting. On this basis, the ICML report was focused on the most topical, interesting or thought-provoking issues in the treatment of lymphoma.
机译:2011年6月15日至18日在瑞士卢加诺举行了第11届国际淋巴瘤国际会议(ICML),该会议是专门针对淋巴瘤的基础和临床研究的主要国际论坛。2011年,来自76个国家的3200名淋巴瘤专家参加了会议会议。 ICML代表了最重要的论坛,用于讨论与全球恶性淋巴瘤治疗相关的基础研究,临床数据和试验结果的各个方面。霍奇金淋巴瘤和非霍奇金淋巴瘤的发病率正在增加。淋巴瘤的治疗是异质性的,通过标准化学疗法,免疫疗法,大剂量化学疗法以及移植和放射疗法可以看到有效的结果。淋巴瘤生长的生物学基础解释了在单一疗法中或与巩固方案结合使用实验性新药的理由。结果令人鼓舞,在会议期间讨论了这些问题。在此基础上,ICML报告将重点放在淋巴瘤治疗中最热门,最有趣或发人深省的问题上。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号